Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Free e-Mail Client Login
biotechdaily.com
Drug Discovery
Features Subscription Partner Sites Journal Info
THERMO FISHER SCIENTIFICGenologicsROCHE APPLIED SCIENCE

Experimental Osteoporosis Drug Proves Safe at Therapeutic Dosage

By BiotechDaily International staff writers
Posted on 26 Jan 2010


Researchers have established the therapeutic window and optimal safe dosage of parathyroid hormone-related protein (PTHrP), an experimental drug being tested for treatment of osteoporosis.

Investigators at the University of Pittsburgh School of Medicine (PA, USA) conducted a single-blinded, two-part, dose-escalating clinical trial that involved 41 healthy postmenopausal women between the ages of 45 and 75. Each subject received either PTHrP or a placebo in a dose-escalating regimen for a period of three weeks. During this period, safety measures (hypercalcemia, nausea, vomiting, hemodynamics, flushing, etc.) and bone turnover markers were measured.

Results of the study were published in the January 8, 2010, online edition of the Journal of Clinical Endocrinology and Metabolism. They revealed that daily doses of 500 and 625 micrograms could be tolerated without serious adverse events. Subjects receiving 750 micrograms per day developed mild hypercalcemia. Bone turnover markers suggested that even at the highest doses, daily treatment with PTHrP did not activate bone resorption (break down). When hypercalcemia occurred, it may have resulted not from bone resorption but from activation of intestinal calcium absorption by 1,25 dihydroxyvitamin D.

"When we studied PTHrP several years ago in small numbers of postmenopausal women with osteoporosis, we found that bone density increased by nearly 5% after only three months of treatment," said senior author Dr. Andrew F. Stewart, professor of endocrinology and metabolism at the University of Pittsburgh School of Medicine. "And even at the highest doses, the side effects were negligible."

A follow-up study will compare results of treatment with PTHrP to those obtained with teriparitide, a drug that already is FDA-approved for osteoporosis treatment. The study will involve 105 participants.

"We are very eager to find out how this new drug compares to a therapy that is currently available," said first author Dr. Mara Horwitz, assistant professor of medicine at the University of Pittsburgh School of Medicine. "Our previous studies suggest that it may increase bone density more dramatically with fewer side effects, but this is the first head-to-head comparison."

Related Links:

University of Pittsburgh School of Medicine





Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to BiotechDaily.com and get complete access to news and events that shape the world of biotechnology.
Free digital version edition of Bio Research International sent by email on regular basis
Free print version of Bio Research International magazine
(available only outside USA and Canada).
Free and unlimited access to back issues of Bio Research International in digital format
Free Bio Research International Newsletter sent every 2 weeks containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!


Click here to Register

Sign in: Registered website members
Username: Password:
Forgot username/password? Click here!
Sign in: Registered magazine subscribers
Subcode: Last Name:
What is SUBCODE?

ADVERTISEMENT
WATERS CORPORATION



Microscopy Illumination
Microscopy Illumination
Bioprocess Vessels
Bioprocess Vessels
Storage Products
Storage Products

More Products

Latest Drug Discovery News

Latest Issue
View Digital Edition
Subscribe / Renew
LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured MedBiz Market Reports
Premium Report Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook
Featured Whitepaper
WATERS CORPORATION:
Ion Exchange Chromatography (SEC) Using the New Waters ACQUITY UPLC H-Class Bio System

Download Whitepaper
Events
17th International Conference on Neuropathology
11 Sep 2010
15 Sep 2010


ADAPT 2010 – Accelerating Development & Advancing Personalized Therapy
13 Sep 2010
16 Sep 2010


Analytica China 2010
15 Sep 2010
17 Sep 2010


More events
THERMO FISHER SCIENTIFIC'
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
BMG LABTECH
THERMO FISHER SCIENTIFIC
Reed Expositions France
WEALTEC BIOSCIENCE
  biotechdaily.com Copyright � 2000-2010 Globetech Media. All rights reserved.